Jong-Hon Kang
Overview
Explore the profile of Jong-Hon Kang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, et al.
Intern Med
. 2024 Jul;
64(3):337-342.
PMID: 38960681
Objective Metabolic-associated fatty liver disease (MAFLD) has only recently been proposed; therefore, the characteristics of patients with autoimmune hepatitis (AIH) and MAFLD remain unclear. This study evaluated the effect of...
2.
Ohira H, Takahashi A, Zeniya M, Abe M, Arinaga-Hino T, Joshita S, et al.
Hepatol Res
. 2022 May;
52(7):571-585.
PMID: 35533021
No abstract available.
3.
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, et al.
Hepatol Res
. 2022 Mar;
52(7):597-602.
PMID: 35355374
Aim: Some autoimmune hepatitis (AIH) patients experience relapse during their clinical course, and some risk factors for relapse have been identified previously using a relatively small sample size. The aim...
4.
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
Nagura Y, Matsuura K, Iio E, Fujita K, Inoue T, Matsumoto A, et al.
PLoS One
. 2022 Feb;
17(2):e0263844.
PMID: 35157730
We examined the association between serum miRNA (-192-5p, -122-3p, -320a and -6126-5p) levels and the efficacy of pegylated interferon (Peg-IFN) monotherapy for chronic hepatitis B (CHB) patients. We enrolled 61...
5.
Tanaka K, Tsuji K, Matsui T, Kang J, Sakurai Y, Kodama Y, et al.
JGH Open
. 2022 Jan;
6(1):36-43.
PMID: 35071786
Background And Aim: With the control of viral hepatitis, alcoholic hepatocellular carcinoma (HCC) is becoming increasingly important in Japan. In alcoholic cirrhosis, the impact of portal hypertension is significant. Thus,...
6.
Takahashi A, Abe M, Yasunaka T, Arinaga-Hino T, Abe K, Takaki A, et al.
Medicine (Baltimore)
. 2020 Oct;
99(43):e22764.
PMID: 33120784
Health-related quality of life (HRQOL) is lower in individuals with autoimmune hepatitis (AIH) than in the general population. However, previous evaluations of HRQOL for AIH have included a broad range...
7.
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, et al.
Sci Rep
. 2020 Aug;
10(1):14250.
PMID: 32859968
The Japanese diagnostic guidelines for autoimmune hepatitis (AIH) were proposed in 2014. This study aimed to determine the trends and characteristics of AIH based on a Japanese nationwide survey. Data...
8.
Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, et al.
J Gastroenterol
. 2020 Jul;
55(10):977-989.
PMID: 32666202
Background: A prospective pilot study of tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (P-IFN) add-on therapy was conducted to evaluate its efficacy in reducing viral antigen levels in...
9.
Yagi M, Matsumoto K, Komori A, Abe M, Hashimoto N, Inao M, et al.
Liver Int
. 2020 May;
40(8):1926-1933.
PMID: 32438508
Background/purpose: Although ursodeoxycholic acid (UDCA) is a first-line treatment for primary biliary cholangitis (PBC), 20%-30% of patients with PBC exhibit an incomplete response to UDCA. Recently, the UDCA Response Score...
10.
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, et al.
Med Mol Morphol
. 2020 May;
54(1):8-13.
PMID: 32410010
Histopathology is essential for the diagnosis and evaluation of disease activity of autoimmune hepatitis (AIH). We aimed to elucidate the characteristics of AIH from the localization of inflammation. We re-evaluated...